SLN News
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 20, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?
Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders? Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 20, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 NEW YORK, Oct. 20, 2026 /PRNewswire/ -- Market Updates News Commentary- Two unrelated...
PR Newswire
Does Silence Therapeutics (SLN) Have the Potential to Rally 82.84% as Wall Street Analysts Expect?
The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In 'Extreme Fear' Zone
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.read more...
Benzinga
Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.read more...
Benzinga
Big Money, Bold Science, and Next Wave of Biotech Catalysts
Biotechnology is delivering a fresh wave of developments that could reshape investor expectations for Disc Medicine (NASDAQ:IRON), Silence Therapeutics (NASDAQ:SLN), NeOnc Technologies Holdings (NASDAQ:NTHI), and Alaunos Therapeutics (NASDAQ:TCRT).
24-7 Market News
SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Silence Therapeutics plc (NASDAQ: SLN) to Merck for $20.00 in cash per American Depositary Share.Halper Sadeh encourages Silence shareholders to click here to learn more about their rights and options or contact Daniel...
Business Wire
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Silence Therapeutics plc (Nasdaq: SLN) (Silence), a biotechnology company developing precision engineered medicines using its proprietary siRNA technology, today announced that it has entered into a definitive agreement with Merck KGaA, Darmstadt, Germany, pursuant to which Merck KGaA, Darmstadt...
Business Wire
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks